Comparatively, the failure of current anti-inflammatory medications against cachexia, might be more an issue of specificity rather than an argument against this overarching concept.2 The involvement of the non-canonical NF-κB pathway activation and the specific involvement of OSM as secreted EDA2R inducer in the presented study provide a beacon of hope toward a more specific understanding of muscle loss and novel therapeutic approaches. This evidence concerns the gene EDA2R and Cachexia.